LOADING
Tag: MildtoModerate
Alphyn Biologics Presents New Data from Phase 2a Trial Showing Significant Improvement of Mild-to-Moderate Atopic Dermatitis
July 10, 2023
– Statistically significant improvements in IGA (Investigator Global Assessment) and EASI ( Eczema Area and Severity Index) scores – Fast itch reduction by day 4 and sustained itch reduction – Body Surface Area (BSA) reduction of at least 50 percent – Significant improvement in Skin Infection Rating Scale (SIRS) ANNAPOLIS, Md. , July 10, 2023 […]
chat_bubble0 Comment
visibility253 Views